Disclaimer PubMed and NLM
1.
Unique features of central neuropathic pain in multiple sclerosis: Results of a cluster analysis. Rivel M, Achiron A, Dolev M, Stern Y, Zeilig G, Defrin R.
Eur J Pain. 2022 Mar 9. doi: 10.1002/ejp.1934. Online ahead of print.
PMID: 35263811
2.
[Work Participation after Multimodal Rehabilitation due to Neurological Diseases – Representative Analyses Using Routine Data of the German Pension Insurance]. Streibelt M, Zollmann P, Rasch L, Schimichowski J, Schmitz S.
Rehabilitation (Stuttg). 2022 Mar 9. doi: 10.1055/a-1726-6845. Online ahead of print.
PMID: 35263791 German.
3.
Peginterferon beta-1a concentrations in breast milk of lactating multiple sclerosis patients. Houtchens M, Mahlanza T, Ciplea AI, Manieri MC, Ramia NF, Zhao Y, England S, Avila R, Altincatal A, Vignos M, Hellwig K.
Mult Scler Relat Disord. 2022 Feb 20;60:103700. doi: 10.1016/j.msard.2022.103700. Online ahead of print.
PMID: 35263702
4.
How does Epstein-Barr virus trigger MS? Kuchroo VK, Weiner HL.
Immunity. 2022 Mar 8;55(3):390-392. doi: 10.1016/j.immuni.2022.02.008.
PMID: 35263566
5.
Demyelinating Events Following Anti-tumor necrosis factor alpha therapy; rare but challenging to treat. Kalén E, Piehl F, Andersson M.
Eur J Neurol. 2022 Mar 9. doi: 10.1111/ene.15318. Online ahead of print.
PMID: 35262993
6.
Remote Assessments of Hand Function in Neurological Disorders: Systematic Review. Gopal A, Hsu WY, Allen DD, Bove R.
JMIR Rehabil Assist Technol. 2022 Mar 9;9(1):e33157. doi: 10.2196/33157.
PMID: 35262502 Review.
7.
Systematic overviews of partnership principles and strategies identified from health research about spinal cord injury and related health conditions: A scoping review. Hoekstra F, Trigo F, Sibley KM, Graham ID, Kennefick M, Mrklas KJ, Nguyen T, Vis-Dunbar M; SC. I. Guiding Principles Consensus Panel, Gainforth HL.
J Spinal Cord Med. 2022 Mar 9:1-18. doi: 10.1080/10790268.2022.2033578. Online ahead of print.
PMID: 35262473
8.
Quantitative susceptibility mapping versus phase imaging to identify multiple sclerosis iron rim lesions with demyelination. Huang W, Sweeney EM, Kaunzner UW, Wang Y, Gauthier SA, Nguyen TD.
J Neuroimaging. 2022 Mar 9. doi: 10.1111/jon.12987. Online ahead of print.
PMID: 35262241
9.
Diagnosis, differential diagnosis and misdiagnosis of Susac syndrome. Triplett JD, Qiu J, O’Brien B, Gopinath S, Trewin B, Spring PJ, Shaffi M, Ip J, Chan F, Chen L, Wilson I, Muller C, Beadnall HN, Boggild M, Van der Walt A, Roxburgh R, Seery N, Kalincik T, Barnett MH, Parratt JDE, Reddel SW, Tsang B, Hardy TA.
Eur J Neurol. 2022 Mar 9. doi: 10.1111/ene.15317. Online ahead of print.
PMID: 35262238
10.
Recommendations to Address the Unique Clinical and Psychological Needs of Transgender Persons Living With Multiple Sclerosis. Sullivan A, Kane A, Valentic G, Rensel M.
Int J MS Care. 2022 Jan-Feb;24(1):35-40. doi: 10.7224/1537-2073.2021-066. Epub 2022 Feb 25.
PMID: 35261570 Free PMC article.
11.
Effects of Sensory Interventions on Fatigue in People With Multiple Sclerosis: A Systematic Review. Mohebbirad M, Motaharinezhad F, Shahsavary M, Joveini G.
Int J MS Care. 2022 Jan-Feb;24(1):29-34. doi: 10.7224/1537-2073.2020-123. Epub 2021 May 24.
PMID: 35261569 Free PMC article.
12.
Effect of Functional Electrical Stimulation Cycling Exercise on Lower Limb Strength Asymmetry in Persons With Multiple Sclerosis. Farrell JW 3rd, Edwards T, Motl RW, Pilutti LA.
Int J MS Care. 2022 Jan-Feb;24(1):25-28. doi: 10.7224/1537-2073.2020-059. Epub 2021 May 17.
PMID: 35261568 Free PMC article.
13.
Validity and Reliability of the Scale to Report Emotional Stress Signs-Multiple Sclerosis (STRESS-MS) in Assessing Abuse and Neglect of Adults With Multiple Sclerosis. Morrison EH, Sorkin D, Mosqueda L, Ayutyanont N.
Int J MS Care. 2022 Jan-Feb;24(1):18-24. doi: 10.7224/1537-2073.2020-016. Epub 2021 Jun 30.
PMID: 35261567 Free PMC article.
14.
Progressive Multifocal Leukoencephalopathy Risk Perception in Patients Considering Natalizumab for Multiple Sclerosis. Berkovich R, Eskenazi J, Yakupova A, Riddle EL.
Int J MS Care. 2022 Jan-Feb;24(1):13-17. doi: 10.7224/1537-2073.2020-068. Epub 2021 Apr 8.
PMID: 35261566 Free PMC article.
15.
Physical Activity and Sedentary Behavior Patterns Across Weekdays and Weekend Days in Youth With Multiple Sclerosis and Controls. Sikes EM, Iruthayanathan R, Grover SA, Viguiliouk E, Kamani Z, Stephens S, Berenbaum T, Noguera A, Ebrahimi N, O’Mahony J, Narang I, Weiss SK, Finlayson M, Banwell B, Marrie RA, Yeh EA, Motl RW.
Int J MS Care. 2022 Jan-Feb;24(1):8-12. doi: 10.7224/1537-2073.2020-056. Epub 2021 May 6.
PMID: 35261565 Free PMC article.
16.
Exploring Self-management Needs of Persons With Multiple Sclerosis: A Qualitative Study for Mobile Application Development. Damanabi S, Salimzadeh Z, Kalankesh LR, Shaafi S, Ferdousi R.
Int J MS Care. 2022 Jan-Feb;24(1):1-7. doi: 10.7224/1537-2073.2019-129. Epub 2021 Apr 16.
PMID: 35261564 Free PMC article.
17.
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Arnold DL, Piani-Meier D, Bar-Or A, Benedict RH, Cree BA, Giovannoni G, Gold R, Vermersch P, Arnould S, Dahlke F, Hach T, Ritter S, Karlsson G, Kappos L, Fox RJ; EXPAND Clinical Investigators.
Mult Scler. 2022 Mar 9:13524585221076717. doi: 10.1177/13524585221076717. Online ahead of print.
PMID: 35261318
18.
Regulating the discriminatory response to antigen by T cell receptor. Gangopadhyay K, Roy S, SenGupta S, Chandradasan AC, Chowdhury S, Das R.
Biosci Rep. 2022 Mar 9:BSR20212012. doi: 10.1042/BSR20212012. Online ahead of print.
PMID: 35260878
19.
B-cell-depletion reverses dysbiosis of the microbiome in multiple sclerosis patients. Troci A, Zimmermann O, Esser D, Krampitz P, May S, Franke A, Berg D, Leypoldt F, Stürner KH, Bang C.
Sci Rep. 2022 Mar 8;12(1):3728. doi: 10.1038/s41598-022-07336-8.
PMID: 35260584
20.
Analysis of CSF D-Dimer to Identify Intrathecal Fibrin-Driven Autoimmunity in Patients With Multiple Sclerosis. Schaller-Paule MA, Yalachkov Y, Steinmetz H, Friedauer L, Hattingen E, Miesbach W, Weber F, Kirchmayr K, Schaefer JH, Foerch C.
Neurol Neuroimmunol Neuroinflamm. 2022 Mar 8;9(3):e1150. doi: 10.1212/NXI.0000000000001150. Print 2022 May.
PMID: 35260469
21.
Tools for comprehensive evaluation of sexual function in patients with multiple sclerosis. Gaviria Carrillo M, Ortiz Salas PA, Rueda Vergara KP, Cortes Bernal GA, Nava Mesa M, Moreno Medina K.
Neurologia (Engl Ed). 2022 Mar 5:S2173-5808(22)00016-5. doi: 10.1016/j.nrleng.2020.04.024. Online ahead of print.
PMID: 35260364 Review.
22.
Immunosenescence: the role of age in multiple sclerosis. Ostolaza Ibáñez A, Corroza Laviñeta J, Ayuso Blanco T.
Neurologia (Engl Ed). 2022 Mar 5:S2173-5808(22)00017-7. doi: 10.1016/j.nrleng.2020.05.023. Online ahead of print.
PMID: 35260362 Review.
23.
Familial multiple sclerosis in patients with Von Hippel-Lindau disease. Nath SR, Grewal P, Cho T, Mao-Draayer Y.
BMC Neurol. 2022 Mar 8;22(1):80. doi: 10.1186/s12883-022-02604-6.
PMID: 35260109
1.
Acupuncture for multiple sclerosis: A literature review. Khodaie F, Abbasi N, Kazemi Motlagh AH, Zhao B, Naser Moghadasi A.
Mult Scler Relat Disord. 2022 Feb 26;60:103715. doi: 10.1016/j.msard.2022.103715. Online ahead of print.
PMID: 35259684 Review.
2.
Measuring cognitive function by the SDMT across functional domains: Useful but not sufficient. Leach JM, Cutter G, Golan D, Doniger G, Zarif M, Bumstead B, Buhse M, Kaczmarek O, Sethi A, Covey T, Penner IK, Wilken J, Gudesblatt M.
Mult Scler Relat Disord. 2022 Feb 20;60:103704. doi: 10.1016/j.msard.2022.103704. Online ahead of print.
PMID: 35259683
3.
Evaluating the impact of the Understanding Multiple Sclerosis online course on participant MS knowledge, health literacy, resilience, self-efficacy, quality of life, and MS symptom severity. Bessing B, van der Mei I, Taylor BV, Honan CA, Blizzard L, Claflin SB.
Mult Scler Relat Disord. 2022 Mar 3;60:103717. doi: 10.1016/j.msard.2022.103717. Online ahead of print.
PMID: 35259682
4.
Antibiotic treatment during pregnancy and lactation in dams exacerbates clinical symptoms and inflammatory responses in offspring with experimental autoimmune encephalomyelitis. Salari AA, Jand Y, Ghazi-Khansari M.
J Neuroimmunol. 2022 Mar 3;366:577840. doi: 10.1016/j.jneuroim.2022.577840. Online ahead of print.
PMID: 35259641
5.
Acute effects of axial loading on postural control during walking and turning in people with multiple sclerosis: A pilot study. Little C, Moore C, Bean E, Peters DM, McGinnis RS, Kasser SL.
Gait Posture. 2022 Mar 3;94:102-106. doi: 10.1016/j.gaitpost.2022.02.031. Online ahead of print.
PMID: 35259637
6.
Microstructural white matter abnormalities in multiple sclerosis and neuromyelitis optica spectrum disorders: Evaluation by advanced diffusion imaging. Kato S, Hagiwara A, Yokoyama K, Andica C, Tomizawa Y, Hoshino Y, Uchida W, Nishimura Y, Fujita S, Kamagata K, Hori M, Hattori N, Abe O, Aoki S.
J Neurol Sci. 2022 Feb 24;436:120205. doi: 10.1016/j.jns.2022.120205. Online ahead of print.
PMID: 35259556
7.
Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy. Cortesi PA, Antonazzo IC, Gasperini C, Nica M, Ritrovato D, Mantovani LG.
PLoS One. 2022 Mar 8;17(3):e0264123. doi: 10.1371/journal.pone.0264123. eCollection 2022.
PMID: 35259168
8.
Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients : Review. Siger M.
Clin Neuroradiol. 2022 Mar 8. doi: 10.1007/s00062-022-01144-3. Online ahead of print.
PMID: 35258820 Review.
9.
Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan. Isomura Y, Shirai Y, Kuwana M.
Rheumatology (Oxford). 2022 Mar 8:keac136. doi: 10.1093/rheumatology/keac136. Online ahead of print.
PMID: 35258561
10.
Coronaviruses and their relationship with multiple sclerosis: is the prevalence of multiple sclerosis going to increase after the Covid-19 pandemia? Lima M, Aloizou AM, Siokas V, Bakirtzis C, Liampas I, Tsouris Z, Bogdanos DP, Baloyannis SJ, Dardiotis E.
Rev Neurosci. 2022 Mar 7. doi: 10.1515/revneuro-2021-0148. Online ahead of print.
PMID: 35258237 Review.
11.
Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets. Signori A, Ponzano M, Alexandri N, Giovannoni G, Sormani MP.
Eur J Neurol. 2022 Mar 8. doi: 10.1111/ene.15316. Online ahead of print.
PMID: 35258154
12.
Longitudinal relationships between disability and gait characteristics in people with MS. Dreyer-Alster S, Menascu S, Dolev M, Givon U, Magalashvili D, Achiron A, Kalron A.
Sci Rep. 2022 Mar 7;12(1):3653. doi: 10.1038/s41598-022-07734-y.
PMID: 35256705
13.
Vulvovaginal Pyoderma Gangrenosum in a Patient Treated With Ocrelizumab for Multiple Sclerosis. Breneman AN, Eber AE, Haque H, Levine L, Askanase A, Riley CS, Pomeranz MK, Hassan D, Mancebo SE, Polin M, Melamed A, Bordone LA, Rosser M, Gockley A, Gallitano SM.
J Low Genit Tract Dis. 2022 Mar 1. doi: 10.1097/LGT.0000000000000661. Online ahead of print.
PMID: 35256568 No abstract available.
14.
Anaesthetic Management of a Child with West Syndrome Associated with Tuberous Sclerosis Complex at a Remote Location: A Case Report. Hameed M, Ul Haq MI.
Turk J Anaesthesiol Reanim. 2022 Feb;50(1):72-74. doi: 10.5152/TJAR.2021.1273.
PMID: 35256350
15.
ABCB1 gene variants as risk factors and modulators of age of onset of demyelinating disease in Mexican patients. Guerrero Camacho JL, Corona Vázquez T, Flores Rivera JJ, Ochoa Morales A, Martínez Ruano L, Torres Ramírez de Arellano I, Dávila Ortiz de Montellano DJ, Jara Prado A.
Neurologia (Engl Ed). 2022 Mar 4:S2173-5808(22)00014-1. doi: 10.1016/j.nrleng.2020.05.021. Online ahead of print.
PMID: 35256320
16.
Attentional networks in neurodegenerative diseases: anatomical and functional evidence from the Attention Network Test. Sarrias-Arrabal E, Izquierdo-Ayuso G, Vázquez-Marrufo M.
Neurologia (Engl Ed). 2022 Mar 4:S2173-5808(22)00015-3. doi: 10.1016/j.nrleng.2020.05.022. Online ahead of print.
PMID: 35256319 Review.
17.
Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases. Jasim SA, Yumashev AV, Abdelbasset WK, Margiana R, Markov A, Suksatan W, Pineda B, Thangavelu L, Ahmadi SH.
Stem Cell Res Ther. 2022 Mar 7;13(1):101. doi: 10.1186/s13287-022-02782-7.
PMID: 35255979 Review.
18.
Fit-for-purpose based testing and validation of antibodies to amino- and carboxy-terminal domains of cannabinoid receptor 1. Echeazarra L, García Del Caño G, Barrondo S, González-Burguera I, Saumell-Esnaola M, Aretxabala X, López de Jesús M, Borrega-Román L, Mato S, Ledent C, Matute C, Goicolea MA, Sallés J.
Histochem Cell Biol. 2021 Nov;156(5):479-502. doi: 10.1007/s00418-021-02025-5. Epub 2021 Aug 27.
PMID: 34453219 Free PMC article.
19.
Intravital Imaging of Neocortical Heterotopia Reveals Aberrant Axonal Pathfinding and Myelination around Ectopic Neurons. Li AM, Hill RA, Grutzendler J.
Cereb Cortex. 2021 Jul 29;31(9):4340-4356. doi: 10.1093/cercor/bhab090.
PMID: 33877363 Free PMC article.
1.
Psychopharmacology of patients with multiple sclerosis in Greece during the period 2017-2019. Bakirtzis C, Karakasi MV, Boziki MK, Moysiadis T, Tsakona D, Fyntanidou B, Papazisis G, Thireos E, Grigoriadis N.
Psychiatriki. 2022 Feb 21. doi: 10.22365/jpsych.2022.057. Online ahead of print.
PMID: 35255462
2.
Breaking the barriers to remyelination in multiple sclerosis. Gharagozloo M, Bannon R, Calabresi PA.
Curr Opin Pharmacol. 2022 Mar 4;63:102194. doi: 10.1016/j.coph.2022.102194. Online ahead of print.
PMID: 35255453 Review.
3.
Serum glial fibrillary acidic protein is a body fluid biomarker: A valuable prognostic for neurological disease – A systematic review. Heimfarth L, Passos FRS, Monteiro BS, Araújo AAS, Quintans Júnior LJ, Quintans JSS.
Int Immunopharmacol. 2022 Mar 4;107:108624. doi: 10.1016/j.intimp.2022.108624. Online ahead of print.
PMID: 35255304 Review.
4.
S1P analogues SEW2871, BAF312 and FTY720 affect human Th17 and Treg generation ex vivo. Zehra Okus F, Busra Azizoglu Z, Canatan H, Eken A.
Int Immunopharmacol. 2022 Mar 4;107:108665. doi: 10.1016/j.intimp.2022.108665. Online ahead of print.
PMID: 35255303
5.
Correction to: The use of Modified Rio score for determining treatment failure in patients with multiple sclerosis: retrospective descriptive case series study. Tutuncu M, Altintas A, Dogan BV, Uygunoglu U, Kale Icen N, Elmali AD, Coban E, Alpaslan BG, Soysal A.
Acta Neurol Belg. 2022 Mar 7. doi: 10.1007/s13760-022-01897-1. Online ahead of print.
PMID: 35254647 No abstract available.
6.
Experimental laboratory biomarkers in multiple sclerosis. Arneth B, Kraus J.
Wien Med Wochenschr. 2022 Mar 7. doi: 10.1007/s10354-022-00920-7. Online ahead of print.
PMID: 35254566
7.
Experiences of receiving a diagnosis of multiple sclerosis: a meta-synthesis of qualitative studies. Topcu G, Mhizha-Murira JR, Griffiths H, Bale C, Drummond A, Fitzsimmons D, Potter KJ, Evangelou N, das Nair R.
Disabil Rehabil. 2022 Mar 7:1-12. doi: 10.1080/09638288.2022.2046187. Online ahead of print.
PMID: 35254195
8.
Genetically predicted coffee consumption and amyotrophic lateral sclerosis. Zhang Z, Wang M, Liu X.
Amyotroph Lateral Scler Frontotemporal Degener. 2022 Mar 7:1-5. doi: 10.1080/21678421.2022.2047204. Online ahead of print.
PMID: 35254179
9.
Identify the report as a systematic review. Kirsty CW, Mary H, Sumner J.
Nutr Health. 2022 Mar 7:2601060221080240. doi: 10.1177/02601060221080240. Online ahead of print.
PMID: 35254171
10.
Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans. Shams H, Shao X, Santaniello A, Kirkish G, Harroud A, Ma Q, Isobe N; University of California San Francisco MS-EPIC Team, Schaefer C, McCauley JL, Cree BAC, Didonna A, Baranzini SE, Patsopoulos NA, Hauser SL, Barcellos LF, Henry RG, Oksenberg JR.
Brain. 2022 Mar 7:awac092. doi: 10.1093/brain/awac092. Online ahead of print.
PMID: 35253861
11.
Factors associated with requesting accommodations among people with multiple sclerosis. Dong S, Mamboleo G.
Work. 2022 Mar 1. doi: 10.3233/WOR-205059. Online ahead of print.
PMID: 35253669
12.
Quality of life and experience with the national multiple sclerosis society strategic plan priorities for people with multiple sclerosis: Findings from a path analysis. Li J, Bishop M, Fraser R, Rumrill PD, LaRocca N, Burns M, Lee D, Bhattarai M.
Work. 2022 Mar 1. doi: 10.3233/WOR-205038. Online ahead of print.
PMID: 35253664
13.
Neurodegeneration and convergent factors contributing to the deterioration of the cytoskeleton in Alzheimer’s disease, cerebral ischemia and multiple sclerosis (Review). Gutiérrez-Vargas JA, Castro-Álvarez JF, Zapata-Berruecos JF, Abdul-Rahim K, Arteaga-Noriega A.
Biomed Rep. 2022 Apr;16(4):27. doi: 10.3892/br.2022.1510. Epub 2022 Feb 18.
PMID: 35251614 Free PMC article. Review.
14.
Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects. Zhang W, Lin H, Zou M, Yuan Q, Huang Z, Pan X, Zhang W.
Front Immunol. 2022 Feb 18;13:826889. doi: 10.3389/fimmu.2022.826889. eCollection 2022.
PMID: 35251010 Free PMC article. Review.
15.
Chemokine-Driven Migration of Pro-Inflammatory CD4+ T Cells in CNS Autoimmune Disease. Heng AHS, Han CW, Abbott C, McColl SR, Comerford I.
Front Immunol. 2022 Feb 16;13:817473. doi: 10.3389/fimmu.2022.817473. eCollection 2022.
PMID: 35250997 Free PMC article. Review.
16.
Circulating Memory B Cells in Early Multiple Sclerosis Exhibit Increased IgA+ Cells, Globally Decreased BAFF-R Expression and an EBV-Related IgM+ Cell Signature. Leffler J, Trend S, Ward NC, Grau GE, Hawke S, Byrne SN, Kermode AG, French MA, Hart PH.
Front Immunol. 2022 Feb 16;13:812317. doi: 10.3389/fimmu.2022.812317. eCollection 2022.
PMID: 35250986 Free PMC article.
17.
Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod. Pournajaf S, Dargahi L, Javan M, Pourgholami MH.
Front Pharmacol. 2022 Feb 16;13:807639. doi: 10.3389/fphar.2022.807639. eCollection 2022.
PMID: 35250559 Free PMC article. Review.
18.
Gut Microbiota Composition Is Related to AD Pathology. Verhaar BJH, Hendriksen HMA, de Leeuw FA, Doorduijn AS, van Leeuwenstijn M, Teunissen CE, Barkhof F, Scheltens P, Kraaij R, van Duijn CM, Nieuwdorp M, Muller M, van der Flier WM.
Front Immunol. 2022 Jan 31;12:794519. doi: 10.3389/fimmu.2021.794519. eCollection 2021.
PMID: 35173707 Free PMC article.
19.
ASK1 signaling regulates phase-specific glial interactions during neuroinflammation. Guo X, Kimura A, Namekata K, Harada C, Arai N, Takeda K, Ichijo H, Harada T.
Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):e2103812119. doi: 10.1073/pnas.2103812119.
PMID: 35101972 Free PMC article.
20.
Successful treatment of systemic sclerosis coexisting with smoldering myeloma. Smoleńska Ż, Gogulska Z, Dorniak K, Zdrojewski Z.
Pol Arch Intern Med. 2021 Dec 22;131(12):16133. doi: 10.20452/pamw.16133. Epub 2021 Oct 26.
PMID: 34698468 No abstract available.
1.
Discovery, synthesis and evaluation of novel reversible monoacylglycerol lipase radioligands bearing a morpholine-3-one scaffold. He Y, Gobbi LC, Herde AM, Rombach D, Ritter M, Kuhn B, Wittwer MB, Heer D, Hornsperger B, Bell C, O’Hara F, Benz J, Honer M, Keller C, Collin L, Richter H, Schibli R, Grether U, Mu L.
Nucl Med Biol. 2022 Feb 23;108-109:24-32. doi: 10.1016/j.nucmedbio.2022.02.002. Online ahead of print.
PMID: 35248850
2.
Pancreatic Neuroendocrine Neoplasms: Updates on Genomic Changes in Inherited Tumour Syndromes and Sporadic Tumours Based on WHO Classification. Ishida H, Lam AK.
Crit Rev Oncol Hematol. 2022 Mar 3:103648. doi: 10.1016/j.critrevonc.2022.103648. Online ahead of print.
PMID: 35248713 Review.
3.
The Genetics and Diagnosis of Pediatric Neurocutaneous Disorders: Neurofibromatosis and Tuberous Sclerosis Complex. Tolliver S, Smith ZI, Silverberg N.
Clin Dermatol. 2022 Mar 3:S0738-081X(22)00025-6. doi: 10.1016/j.clindermatol.2022.02.010. Online ahead of print.
PMID: 35248688
4.
The effectiveness of physical therapy interventions in reducing falls among people with multiple sclerosis: A systematic review and meta-analysis. Abou L, Qin K, Alluri A, Du Y, Rice LA.
J Bodyw Mov Ther. 2022 Jan;29:74-85. doi: 10.1016/j.jbmt.2021.09.015. Epub 2021 Oct 8.
PMID: 35248292 Review.
5.
Epidemiology of familial multiple sclerosis in Iran: a national registry-based study. Salehi Z, Almasi-Hashiani A, Sahraian MA, Ashtari F, Baghbanian SM, Razazian N, Moghadasi AN, Bayati A, Azimi AR, Beladimoghadam N, Harirchian MH, Poursadeghfard M, Navardi S, Shirkoohi R, Heidari H, Ghaffari M, Eskandarieh S.
BMC Neurol. 2022 Mar 5;22(1):76. doi: 10.1186/s12883-022-02609-1.
PMID: 35248009
6.
Multifocal micronodular pneumocyte hyperplasia lacking typical clinical features of the tuberous sclerosis complex: a case report and literature review. Li S, Wu C, Ma Q, Chen X, Zhang W, Li X, Huang M, Ji N.
BMC Pulm Med. 2022 Mar 5;22(1):77. doi: 10.1186/s12890-022-01849-8.
PMID: 35248007
7.
Does physical exercise improve or deteriorate treatment of multiple sclerosis with mitoxantrone? Experimental autoimmune encephalomyelitis study in rats. El-Emam MA, El Achy S, Abdallah DM, El-Abhar HS, Gowayed MA.
BMC Neurosci. 2022 Mar 5;23(1):11. doi: 10.1186/s12868-022-00692-1.
PMID: 35247984
1.
7-deacetyl-gedunin suppresses proliferation of Human rheumatoid arthritis synovial fibroblast through activation of Nrf2/ARE signaling. Chen J, Zhu G, Sun Y, Wu Y, Wu B, Zheng W, Ma X, Zheng Y.
Int Immunopharmacol. 2022 Mar 2;107:108557. doi: 10.1016/j.intimp.2022.108557. Online ahead of print.
PMID: 35247778
2.
A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran. Paybast S, Hejazi SA, Molavi P, Habibi MA, Naser Moghadasi A.
Mult Scler Relat Disord. 2022 Feb 26;60:103712. doi: 10.1016/j.msard.2022.103712. Online ahead of print.
PMID: 35247752
3.
A point-of-care diagnostic test for aquaporin-4 antibody seropositive neuromyelitis optica. Rice DR, Nishiyama S, Pardo S, Cabal Herrera AM, Levy M, Mateen FJ.
Mult Scler Relat Disord. 2022 Feb 27;60:103716. doi: 10.1016/j.msard.2022.103716. Online ahead of print.
PMID: 35247751
4.
QSMRim-Net: Imbalance-aware learning for identification of chronic active multiple sclerosis lesions on quantitative susceptibility maps. Zhang H, Nguyen TD, Zhang J, Marcille M, Spincemaille P, Wang Y, Gauthier SA, Sweeney EM.
Neuroimage Clin. 2022 Mar 1;34:102979. doi: 10.1016/j.nicl.2022.102979. Online ahead of print.
PMID: 35247730
5.
Evaluation of polarity switching for untargeted lipidomics using liquid chromatography coupled to high resolution mass spectrometry. Carlsson H, Vaivade A, Emami Khoonsari P, Burman J, Kultima K.
J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Feb 28;1195:123200. doi: 10.1016/j.jchromb.2022.123200. Online ahead of print.
PMID: 35247679
6.
Surgery for tuberous sclerosis complex-related epilepsy: Risk factors for an unfavorable seizure outcome. d’Orio P, Pelliccia V, Biondi D, Scarpa P, Gozzo F, Revay M, Cardinale F, Tassi L, Cossu M.
Seizure. 2022 Feb 27;97:8-14. doi: 10.1016/j.seizure.2022.02.013. Online ahead of print.
PMID: 35247673
7.
Contemporary advances in antibody-mediated encephalitis: anti-LGI1 and anti-Caspr2 antibody (Ab)-mediated encephalitides. Seery N, Butzkueven H, O’Brien TJ, Monif M.
Autoimmun Rev. 2022 Mar 2:103074. doi: 10.1016/j.autrev.2022.103074. Online ahead of print.
PMID: 35247644 Review.
8.
Delayed B cell repopulation after rituximab treatment in multiple sclerosis patients with expanded adaptive NK cells. Moreira A, Munteis E, Vera A, Macías Gómez A, Bertrán Recasens B, Rubio Pérez MÁ, Llop M, Martínez-Rodríguez JE.
Eur J Neurol. 2022 Mar 5. doi: 10.1111/ene.15312. Online ahead of print.
PMID: 35247022
9.
Transmembrane protein 119 is neither a specific nor a reliable marker for microglia. Vankriekelsvenne E, Chrzanowski U, Manzhula K, Greiner T, Wree A, Hawlitschka A, Llovera G, Zhan J, Joost S, Schmitz C, Ponsaerts P, Amor S, Nutma E, Kipp M, Kaddatz H.
Glia. 2022 Mar 4. doi: 10.1002/glia.24164. Online ahead of print.
PMID: 35246882
10.
Multimodal prognostic features of seizure freedom in epilepsy surgery. Alim-Marvasti A, Vakharia VN, Duncan JS.
J Neurol Neurosurg Psychiatry. 2022 Mar 4:jnnp-2021-327119. doi: 10.1136/jnnp-2021-327119. Online ahead of print.
PMID: 35246493
11.
Eculizumab versus rituximab in generalised myasthenia gravis. Nelke C, Schroeter CB, Stascheit F, Pawlitzki M, Regner-Nelke L, Huntemann N, Arat E, Öztürk M, Melzer N, Mergenthaler P, Gassa A, Stetefeld H, Schroeter M, Berger B, Totzeck A, Hagenacker T, Schreiber S, Vielhaber S, Hartung HP, Meisel A, Wiendl H, Meuth SG, Ruck T.
J Neurol Neurosurg Psychiatry. 2022 Mar 4:jnnp-2021-328665. doi: 10.1136/jnnp-2021-328665. Online ahead of print.
PMID: 35246490
12.
Perfect match: mTOR inhibitors and tuberous sclerosis complex. Luo C, Ye WR, Shi W, Yin P, Chen C, He YB, Chen MF, Zu XB, Cai Y.
Orphanet J Rare Dis. 2022 Mar 4;17(1):106. doi: 10.1186/s13023-022-02266-0.
PMID: 35246210 Review.
13.
Calmodulin binding proteins and neuroinflammation in multiple neurodegenerative diseases. O’Day DH, Huber RJ.
BMC Neurosci. 2022 Mar 4;23(1):10. doi: 10.1186/s12868-022-00695-y.
PMID: 35246032 Review.
1.
Serum metabolic profiles and metal levels of patients with multiple sclerosis and patients with neuromyelitis optica spectrum disorders – NMR spectroscopy and ICP-MS studies. Toczylowska B, Zieminska E, Podlecka-Pietowska A, Ruszczynska A, Chalimoniuk M.
Mult Scler Relat Disord. 2022 Feb 6;60:103672. doi: 10.1016/j.msard.2022.103672. Online ahead of print.
PMID: 35240533
2.
Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic. Hradilek P, Meluzinova E, Zapletalova O, Hanulikova P, Horakova D, Woznicova I, Pavliska L, Stetkarova I, Valis M, Stourac P, Adamkova J, Ampapa R, Vachova M, Mares J.
Mult Scler Relat Disord. 2021 Nov 28;59:103391. doi: 10.1016/j.msard.2021.103391. Online ahead of print.
PMID: 35240415
3.
Do Hungarian multiple sclerosis care units fulfil international criteria? Kokas Z, Sandi D, Fricska-Nagy Z, Füvesi J, Biernacki T, Köves Á, Fazekas F, Birkás AJ, Katona G, Kovács K, Milanovich D, Dobos E, Kapás I, Jakab G, Csépány T, Bense E, Mátyás K, Rum G, Szolnoki Z, Deme I, Jobbágy Z, Kriston D, Gerócs Z, Diószeghy P, Bors L, Varga A, Kerényi L, Molnár G, Kristóf P, Nagy ZÁ, Sátori M, Imre P, Péntek S, Klivényi P, Kincses ZT, Vécsei L, Bencsik K.
PLoS One. 2022 Mar 3;17(3):e0264328. doi: 10.1371/journal.pone.0264328. eCollection 2022.
PMID: 35239686
4.
Exercise-induced increase in blood-based brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis: A systematic review and meta-analysis of exercise intervention trials. Shobeiri P, Karimi A, Momtazmanesh S, Teixeira AL, Teunissen CE, van Wegen EEH, Hirsch MA, Yekaninejad MS, Rezaei N.
PLoS One. 2022 Mar 3;17(3):e0264557. doi: 10.1371/journal.pone.0264557. eCollection 2022.
PMID: 35239684
5.
Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse. Etemadifar M, Nouri H, Salari M, Sedaghat N.
Hum Vaccin Immunother. 2022 Mar 3:1-4. doi: 10.1080/21645515.2022.2033540. Online ahead of print.
PMID: 35239452
6.
MOG-Specific T Cells Lead to Spontaneous EAE with Multilocular B Cell Infiltration in the GF-IL23 Model. Nitsch L, Petzinna S, Zimmermann J, Getts DR, Becker A, Müller M.
Neuromolecular Med. 2022 Mar 3. doi: 10.1007/s12017-022-08705-2. Online ahead of print.
PMID: 35239103
7.
Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis. Mariottini A, Bertozzi A, Marchi L, Di Cristinzi M, Mechi C, Barilaro A, Massacesi L, Repice AM.
J Neurol. 2022 Mar 3. doi: 10.1007/s00415-022-11003-3. Online ahead of print.
PMID: 35239006
8.
Associations of Alcohol Consumption and Smoking With Disease Risk and Neurodegeneration in Individuals With Multiple Sclerosis in the United Kingdom. Kleerekooper I, Chua S, Foster PJ, Trip SA, Plant GT, Petzold A, Patel P; UK Biobank Eye and Vision Consortium.
JAMA Netw Open. 2022 Mar 1;5(3):e220902. doi: 10.1001/jamanetworkopen.2022.0902.
PMID: 35238934
9.
Ni-catalyzed Cross-coupling of 2-Iodoglycals and 2-Iodoribals with Grignard Reagents: A Route to 2-C-Glycosides and 2-C-Nucleosides. Cossy J, Polák P.
Chemistry. 2022 Mar 2. doi: 10.1002/chem.202104311. Online ahead of print.
PMID: 35238093
10.
Visual Search in Naturalistic Scenes Reveals Impaired Cognitive Processing Speed in Multiple Sclerosis. Gehrig J, Bergmann HJ, Fadai L, Soydaş D, Buschenlange C, Naumer MJ, Kaiser J, Frisch S, Behrens M, Foerch C, Yalachkov Y.
Front Neurol. 2022 Feb 14;13:838178. doi: 10.3389/fneur.2022.838178. eCollection 2022.
PMID: 35237231 Free PMC article.
11.
Disabled in Society – A Scoping Review on Persons Living with Multiple Sclerosis and Disability. Ståhl D, Bjereld Y, Dunér A.
J Multidiscip Healthc. 2022 Feb 24;15:375-390. doi: 10.2147/JMDH.S353347. eCollection 2022.
PMID: 35237043 Free PMC article. Review.
12.
Susac syndrome with a unique involvement of the thoracic spinal cord. Mahmoud RA, Ungerer R, Gratton S, Schwartzman MJ.
BMJ Case Rep. 2022 Mar 2;15(3):e247351. doi: 10.1136/bcr-2021-247351.
PMID: 35236690
13.
Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. Demuth S, Guillaume M, Bourre B, Ciron J, Zephir H, Sirejacob Y, Kerbrat A, Lebrun-Frenay C, Papeix C, Michel L, Laplaud D, Vukusic S, Maillart E, Cohen M, Audoin B, Marignier R, Collongues N; NOMADMUS Study Group.
J Neuroinflammation. 2022 Mar 2;19(1):62. doi: 10.1186/s12974-022-02420-2.
PMID: 35236386
14.
Perceptions of physical activity and sedentary behaviour guidelines among end-users and stakeholders: a systematic review. Hollman H, Updegraff JA, Lipkus IM, Rhodes RE.
Int J Behav Nutr Phys Act. 2022 Mar 2;19(1):21. doi: 10.1186/s12966-022-01245-9.
PMID: 35236360 Review.
15.
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases. Wieske L, Kummer LYL, van Dam KPJ, Stalman EW, van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, Volkers AG, D’Haens GRAM, Tas SW, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Killestein J, van Kempen ZLE, Voskuyl AE, Broens B, Sanchez AP, Wolbink G, Boekel L, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart CF, Teng YKO, van Paassen P, Busch MH, Jallah BP, Brusse E, van Doorn PA, Baars AE, Hijnen D, Schreurs CRG, van der Pol WL, Goedee HS, Steenhuis M, Rispens T, Ten Brinke A, Verstegen NJM, Zwinderman KAH, van Ham SM, Kuijpers TW, Eftimov F; T2B! immunity against SARS-CoV-2 study group.
BMC Med. 2022 Mar 2;20(1):100. doi: 10.1186/s12916-022-02310-7.
PMID: 35236350
16.
Rehabilitative interventions for ischaemic digital ulcers, pain, and hand functioning in systemic sclerosis: a prospective before-after study. Scaturro D, Guggino G, Terrana P, Vitagliani F, Falco V, Cuntrera D, Benedetti MG, Moretti A, Iolascon G, Letizia Mauro G.
BMC Musculoskelet Disord. 2022 Mar 2;23(1):193. doi: 10.1186/s12891-022-05145-8.
PMID: 35236311
17.
A possible causal involvement of neuroinflammatory, purinergic P2X7 receptors in psychiatric disorders. Zhang Y, Yin HY, Rubini P, Tang Y, Illes P.
Curr Neuropharmacol. 2022 Mar 2. doi: 10.2174/1570159X20666220302152400. Online ahead of print.
PMID: 35236262
18.
Pathways to cures for multiple sclerosis: A research roadmap. Bebo BF Jr, Allegretta M, Landsman D, Zackowski KM, Brabazon F, Kostich WA, Coetzee T, Ng AV, Marrie RA, Monk KR, Bar-Or A, Whitacre CC.
Mult Scler. 2022 Mar;28(3):331-345. doi: 10.1177/13524585221075990.
PMID: 35236198
19.
Neutralizing anti-IL-1 receptor antagonist autoantibodies induce inflammatory and fibrotic mediators in IgG4-related disease. Jarrell JA, Baker MC, Perugino CA, Liu H, Bloom MS, Maehara T, Wong HH, Lanz TV, Adamska JZ, Kongpachith S, Sokolove J, Stone JH, Pillai SS, Robinson WH.
J Allergy Clin Immunol. 2022 Jan;149(1):358-368. doi: 10.1016/j.jaci.2021.05.002. Epub 2021 May 8.
PMID: 33974929
Napsat komentář
Pro přidávání komentářů se musíte nejdříve přihlásit.